Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Jurjen Versluis, Yael Flamand, MS, Erika J. Haydu, MD PhD, Rahul S. Vedula, MD, Anne Charles, BS, Kevin Copson, MA, Ofir Wolach, MD, Pavan Bendapudi, MD, Roger Belizaire, MD PhD, Donna S. Neuberg, ScD, Marlise R Luskin, MDMS, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137741

Published: 2020

Journal Articles

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Ofir Wolach, MD, Itai Levi, MD, Jonathan Canaani, MD, Tamar Tadmor, MD, Sigal Tavor, MD, Ilana Hellmann, MD, Tsila Zuckerman, MD, David Lavie, MD, Galia Stemer, MD, Raanan Cohen, MD, Ran Afik, PhD, Keren Ofek, PhD, Hilla Banayan, BSc MBA, Inna Kan, PhD, Moshe Grunspan, PhD, Yishai Ofran, MD, Yakir Moshe, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-139923

Published: 2020

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134789

Published: 2020

Journal Articles

Diarrheal Morbidity in Patients Undergoing Hematopoietic Cell Transplantation - the Diagnostic Yield of Stool Cultures

Tamar Berger, MD, Odil Giladi, MD, Dafna Yahav, MD, Haim Ben-Zvi, Oren Pasvolsky, MD, Liat Shargian-Alon, MD, Ofir Wolach, MD, Uri Rozovski, MD, Pia Raanani, MD, Moshe Yeshurun, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-138630

Published: 2020

Journal Articles

The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment

Tamar Berger, MD, Ofir Wolach, MD, Shany Sherman, MD, Adi Shacham Abulafia, MD, Pia Raanani, MD, Oren Pasvolsky, MD

Blood (2019) 134 (Supplement_1): 5110.

https://doi.org/10.1182/blood-2019-125133

Published: 2019

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Analysis of Elderly Patients (≥70 years old) with Acute Leukemia in the Era of Targeted Therapy

Alon Rozental, MD, Shai Shimony, MD, Pia Raanani, MD, Ofir Wolach, MD

Blood (2019) 134 (Supplement_1): 5100.

https://doi.org/10.1182/blood-2019-121904

Published: 2019

Journal Articles

Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia

Oren Pasvolsky, MD, Pnina Dorfman Etrog, Ofir Wolach, MD, Karyn Geiger, Orit Horn, Amiad Abrahams, Pia Raanani, MD, Uri Rozovski, MD

Blood (2019) 134 (Supplement_1): 5899.

https://doi.org/10.1182/blood-2019-130908

Published: 2019

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD

Blood (2019) 134 (Supplement_1): 2662.

https://doi.org/10.1182/blood-2019-125966

Published: 2019

Journal Articles

Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study

Tamar Berger, MD, Yakir Moshe, MD, Shilo Yaari, Ilana Hellmann, MD, Adina Aviram, PhD, Pia Raanani, Ron Ram, MD, Yishai Ofran, MD, Ofir Wolach, MD

Blood (2018) 132 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2018-99-114154

Published: 2018

Journal Articles

Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study

Ron Ram, MD, Odelia Amit, MD, Tsila Zuckerman, MD, Ronit Gurion, Pia Raanani, Yael Bar-On, MD, Irit Avivi, MD, Ofir Wolach, MD

Blood (2018) 132 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2018-99-113596

Published: 2018

Journal Articles

Sequential Treatment with FLAG-IDA Salvage Chemotherapy Followed By Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia

Liat Shargian-Alon, MD, Ofir Wolach, MD, Oren Pasvolsky, Pia Raanani, Moshe Yeshurun

Blood (2018) 132 (Supplement 1): 5788.

https://doi.org/10.1182/blood-2018-99-117301

Published: 2018

Journal Articles

Risk Factors for Early Mortality in Hemato-Oncological Patients with Carbapenem Resistant Acinetobacter Baumannii (CRAB) Bacteremia

Liat Shargian-Alon, MD, Anat Gafter-Gvili, Ofir Wolach, MD, Moshe Yeshurun, Pia Raanani, Dafna Yahav, MD

Blood (2018) 132 (Supplement 1): 4953.

https://doi.org/10.1182/blood-2018-99-114165

Published: 2018

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Causes Accelerated Aging Both of the Hematopoietic and Somatic Systems

Moshe Yeshurun, Meir Lahav, MD, Uri Rozovski, Einat Beery, Liat Shargian, MD, Maya Moshe, Michal Navon Sela, Anat Peck, Iuliana Vaxman, MD, Ofir Wolach, MD, Pia Raanani, Orit Uziel, PhD

Blood (2017) 130 (Supplement 1): 333.

https://doi.org/10.1182/blood.V130.Suppl_1.333.333

Published: 2017

Journal Articles

Effect of Anthracycline Dose on Acute Anthracycline Induced Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation

Oren Pasvolsky, MD, Olga Morelli, MD, Uri Rozovski, Moti Vaturi, MD, Ofir Wolach, MD, Irina Amitai, MD, Iuliana Vaxman, MD, Roy Ratzon, MD, Moshe Yeshurun, Zaza Iakobishvili, MD, Ran Kornowski, MD, Pia Raanani

Blood (2017) 130 (Supplement 1): 3861.

https://doi.org/10.1182/blood.V130.Suppl_1.3861.3861

Published: 2017

Journal Articles

Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation

Ofir Wolach, MD, Rob S Sellar, MD, Kimberly Martinod, PhD, Marie E. McConkey, PhD, Alexander J. Silver, B.S., Ryan Chappell, Richard M. Stone, MD, Martha Wadleigh, MD, David P Steensma, MD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, MSN, ANPc, Rebekka K. Schneider, MD, Robert F. Padera, MD PhD, Ann Mullally, MD, Denisa D. Wagner, PhD, Benjamin L. Ebert, MD PhD

Blood (2016) 128 (22): 633.

https://doi.org/10.1182/blood.V128.22.633.633

Published: 2016

Journal Articles

Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center

Ofir Wolach, MD, Kristen Stevenson, MS, Martha Wadleigh, MD, Daniel J. DeAngelo, MD PhD, David P. Steensma, MD, Robert J. Soiffer, MD, Joseph H Antin, MD, Donna S Neuberg, ScD, Vincent T. Ho, MD, Richard M. Stone, MD

Blood (2015) 126 (23): 1304.

https://doi.org/10.1182/blood.V126.23.1304.1304

Published: 2015

Journal Articles

Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation

Shannon Elf, PhD, Nouran Abdelfattah, MPhil, Edwin Chen, PhD, Javier Perales-Patón, Emily Rosen, BS, Amy Ko, Fabian Peisker, Natalie Florescu, Silvia Giannini, PhD, Ofir Wolach, MD, Elizabeth A. Morgan, MD, Julie-Aurore Losman, MD, PhD, Rebekka K. Schneider, MD, Fatima Al-Shahrour, PhD, Ann Mullally, MD

Blood (2015) 126 (23): LBA-4.

https://doi.org/10.1182/blood.V126.23.LBA-4.LBA-4

Published: 2015

NARROW

Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1 st Line Therapies in Patients with Acute Myeloid Leukemia (AML) - Revive Study

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Diarrheal Morbidity in Patients Undergoing Hematopoietic Cell Transplantation - the Diagnostic Yield of Stool Cultures

The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Analysis of Elderly Patients (≥70 years old) with Acute Leukemia in the Era of Targeted Therapy

Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study

Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study

Sequential Treatment with FLAG-IDA Salvage Chemotherapy Followed By Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia

Risk Factors for Early Mortality in Hemato-Oncological Patients with Carbapenem Resistant Acinetobacter Baumannii (CRAB) Bacteremia

Allogeneic Hematopoietic Cell Transplantation Causes Accelerated Aging Both of the Hematopoietic and Somatic Systems

Effect of Anthracycline Dose on Acute Anthracycline Induced Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation

Thrombosis in Myeloproliferative Neoplasms Is Linked to Increased Neutrophil Extracellular Trap (NET) Formation

Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center

Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only